Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amgen presents denosumab data

AMGN said late Friday that denosumab significantly increased lumbar spine bone mineral density (BMD) vs. placebo at

Read the full 171 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE